Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) had its price objective reduced by HC Wainwright from $6.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2023 earnings at ($1.30) EPS, FY2023 earnings at ($6.26) […]
HC Wainwright reissued their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) in a report published on Wednesday morning, Marketbeat reports. They currently have a $6.00 target price on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2023 earnings at ($1.43) EPS, Q4 2023 earnings at ($0.81) EPS, FY2023 […]
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) saw a large growth in short interest in July. As of July 15th, there was short interest totalling 30,000 shares, a growth of 18.1% from the June 30th total of 25,400 shares. Based on an average trading volume of 487,600 shares, the days-to-cover ratio is presently 0.1 […]